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Abstract
  
 Heliannuols are sesquiterpenes lactone compounds considered to have anticancer 
activity on the brain cancer. Cancer cell growth is related to overexpression of Vascular 
Endothelial Growth Factor Receptor-2 (VEGFR-2) as a pro-angiogenic pathway, which 
becomes the main factor of angiogenesis and progression. This research aims to predict 
anti-angiogenic, toxicity, and physicochemical properties of heliannuols. Physicochemical 
properties were predicted referred to Lipinski’s rule of five (Lipinski RO5), while absorption, 
distribution, metabolism, and excretion were predicted by using pkCSM online tool. The 
toxicity of compounds was predicted by using Protox II online tool, and interaction of 
the ligand with receptors was predicted by conducting validation (VEGFR-2 (PDB ID: 
3WZE)) and molecular docking using Molegro Virtual Docker (MVD). The result revealed 
that Lipinski RO5 compatible heliannuols had the lowest LD50 2148 mg/kg predictive LD50 
predictive values of heliannuol D. The docking result was described by rerank score (RS), 
representing the bound energy form and compares with Sorafenib as a reference drug. Five 
medium strength VEGFR-2 chemical substances with rerank score: heliannuol A -56.9496, 
heliannuol heliannuol B -70.83646, heliannuol C -61,3292, heliannuol D -49.61646, and 
heliannuol E -75.5164. No better rerank score was recorded for all inhibitors than sorafenib 
(-128.0683). The heliannuols interacted with amino acid residues Glu885 and Asp1046 
that probably conferred the antiangiogenic activity. Taken together, heliannuol D had the 
greates activity to the target protein and complied Lipinski RO5.  
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INTRODUCTION 
 Brain cancer is an abnormal mass in the 
body caused by excessive multiplication of cells 
and causes the process of space pressure (Talo, et 
al., 2019). Brain cancer is the third leading cause of 
death at the age of under the age of 20 years and the 
age of 20-39 (Ministry of Health, 2017). The global 
incidence of brain cancer is 4.25 cases in 100,000 
people (Bell, et al., 2019).
 Surgery, chemotherapy and radiotherapy 
are intensive treatment efforts. However, these 
treatments have not been able effectively to tackle 
cancer (Conze, 2001). Therefore, it is necessary to 
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develop anticancer drugs using natural substance.
Components predict to have chemopreventive 
agent activity are heliannuol which is contained 
in Helianthus annuus and belongs to the lactone 
sesquiterpenes class. Heliannuol compounds are 
reported to be able to cross the blood brain barrier 
(BBB) in the in silico physicochemical properties 
study (Firdausy, et al., 2020). The BBB being the 
tightest endothelium in the body also represents 
the main impediment to drug delivery to the brain 
(Bellettato and Scarpa, 2018). Therapeutic targeting 
of the BBB is emerging as critically relevant clinical 
goal such as brain cancer (Agarwal, et al., 2011; 
Kesari, 2011; Nico, 2012).
 Inhibition of the Nuclear Factor-kB (NF-
kB) signaling pathway is one of the anticancer 
mechanisms in sesquiterpene lactone compounds 
(Babei, et al., 2018). NF-kB has a major role 
in inhibiting apoptosis, induction of metastasis, 
cell proliferation, cell transformation, invasion, 
metastasis, resistance to chemotherapy, and 
resistance to radiotherapy (Jeroen, et al., 2007; 
Kreunger, et al., 2012).  Some heliannuol compounds 
have benzoxepine rings, where only refer to place 
the ring has anticancer activity through inhibition 
of Phosphoinoside 3-kinase (PI3K). Researchers 
have explored this class of heterocycles as potential 
anticancer agents. The benzoxepine ring seemed 
would able to grant acces to Agr770 and Ser773 
(Heffron, et al., 2011; Kuntala, et al., 2017). 
By inhibiting the receptor, Vascular Endothelial 
Growth Factor Receptor-2 (VEGFR-2) will inhibit 
all signaling pathways (PDB ID: 3WZE).  The  Both 
signaling pathways can be inhibited by inhibiting 
the receptor Vascular Endothelial Growth Factor 
Receptor-2 (VEGFR-2) (PDB ID: 3WZE). 
 Thus, the disorderly tumor vasculature 
observed in the tumors significantly changes the 
microenvironment of the tumor and affects multiple 
aspects of tumor proliferation, such as tumor 
formation, enabling the tumor cells to quickly 
infiltrate and metastasize to distant locations. One 
of the functional approaches to inhibiting tumor 
angiogenesis is to recognize the role of angiogenesis 
in tumor vasculature and inhibition of growth 
factors/signaling pathways essential for endothelial 
cell growth and proliferation.
 Tumors generate abnormal and functionally 
immature blood vessels due to deregulated factors 
such angiogenic growth factor, angiogenesis 
inhibitor, and other genetic factors by a process 
known as pathological angiogenesis (Carmeliet and 
Jain, 2011). Blood vessels developing in the primary 
tumor are larger than their normal counterparts 
and follow a criss-cross path, with irregular lumen 
diameters, dilated, highly permeable and branch 
irregulary (De Bock, et al., 2011). The selection of 
these receptors to block activators of angiogenesis 
is crucial in the field of brain anticancer drug 
discovery which plays a significant role in modulet 
vessel permeability, remodeling, endothelial cell 
survival, proliferation and migration (Knizetova, 
et al., 2008). The rational behind antiangiogenic 
thearphy is the concept that blocking blood vessel 
formation in cancer or its regression would deprive 
cancer cells of nutrients and oxygen and finally 
starve to death or induce tumor dormancy. In 
this study, the researcher performs the prediction 
of the physicochemical properties, toxicity and 
antiangiogenic activity of the heliannuols compound 
to VEGFR-2 (PDB ID: 3WZE).
METHOD AND MATERIALS
Software
 The software used include 3D ChemBio 
program package v.12.0.2 Free Trial (serial number: 
186-410320-7811). The program pkCSM Online 
Tool (Prediction of Pramacokinetics Properties 
Online Tool 2015 by Douglas (http://structure.bioc.
cam.ac.uk/ pkcsm). The program Protox II Online 
Tool (http://accelrys.com/). Molegro Virtual Docker 
(MVD 2013.6.0) program (fully functional, free 
trial version with time limiting license; Molegro 
Virtual Docker (MVD 2013.6.0).
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 The study began with the preparation of 
VEGFR-2 (PDB code: 3WZE) obtained from the 
Protein Data Bank (www.pdb.org). The preparation 
was done by downloading data from PDB 3WZE, 
reducting 3WZE chains into monomeric form using 
SwissPDBViewer v4.1, analysis binding pocket 
by Ligand Explorer Viewer bond in Protein Data 
Bank (www.pdb.org). and Q-siteFinder, analysis of 
ligand-receptor interactions with the Ligan Explorer 
Viewer in the Protein Data Bank (www.pdb.org).
 Subsequently, preparation of ligand 
heliannuols were done by 3D ChemBio package 
v.12.0.2 Free Trial. The ligand preparation was 
started by drawing 2D and 3D ligand structure 
using ChemBio program package 3D v.12.0.2 Free 
Trial.
Target and Template Selection
 PDB ID of VEGFR-2:3WZE with 
resolution 1.90 Å was obtained from protein Data 
Bank (https://www.rcsb. org). The SMILES code 
was obtained from PubChem Compound (https://
pubchem.ncbi.nlm.nih.gov/).
Prediction of Physicochemical Properties 
and Toxicity
 The SMILE code and the pkCSM online 
tool were used to predict physicochemical properties 
and toxicity, and then they were estimated based on 
the Lipinski Law of Five. The online tool Protox II 
was used for toxicity.
 Molecular Docking Study
 Using the MVD software, docking and 
amino acid analysis was carried out. The protocol 
for docking the measures is as follows: Docking 
and amino acids analysis were performed using 
the MVD program. The steps for docking process 
as follows: Selection of proteins target: The PDB 
ID is 3WZE. Determination of bonding position: 
The protein active sites was determined based on 
the ligand positions within a radius of 4.5 Å and 
the presence of important amino acids. Creating 3D 
structures: The 2D chemical structure (flat structure) 
of the compounds was automatically converted 
to the 3D chemical structure (three-dimensional 
structure) by ChemBio Ultra software.  Lowest-
energy state: The 3D molecular structures of the 
compounds were then optimized using MMFF94 
method using the same software. Preparation of 
docks of molecules in protein and simulation. 
Docking compounds into prepared proteins 
and compounds via the MVD program docking 
process with the following options: Moldoc Score 
[Column], Grid resolution 0.3; Ligand assessment: 
Internal ES, Internal Hbond, Sp2-Sp2 Torsion, 
MolDock SE alogarithm, minimization of energy 
and optimization after docking of hydrogen bonds. 
The interaction analysis of compounds and targeted 
proteins. Different associations are plotted, such 
as van der Waals interactions, hydrogen bonds, 
cation-π bonds, π-π bonds, and ionic interactions, 
and the gap of contact between amino acids and 
compound active sites. Van der Waals interactions 
was detected by contact with hydrophilic and 
hydrophobic surfaces between the compounds and 
the bonding point.
RESULTS  
Prediction of Physicochemical Properties 
and Toxicity
 The result of absorption, permeability and 
toxicity prediction of heliannuols using Lipinski’s 
rules of five showed that the four physicochemical 
Figure 1. Receptor of VEGFR-2 (PDB ID: 3WZE).
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properties were Log p<5, molecular weight 
<500, H bond donor<5 and H bond acceptor<10 
(Lipinski, et al., 2001). Based on these results, the 
five heliannuols met the Lipinski’s five rules in 
order to predict that, for example, heliannuol will 
work on effectiveness, protection or metabolism. 
Furthermore, small molecules of drug candidates 
and chemical samples must be properly tested to 
meet their site of operation and to accomplish the 
primary objective. Table 1 shows the predicted 
results of physicochemical properties and toxicity.
Receptor Validation
 Receptor validation was conducted to 
evaluate whether the 3WZE receptor was suitable 
for docking or not. Receptor validation using 
Molegro Virtual Docker 6.0 was done by re-
docking receptor cavity native ligands resulting 
from the receptor validation process, namely the 
RMSD (Root Mean Square Deviation) value with 
an ideal value<2Å (Pratama, 2015). The results of 
receptor validation are shown in Table 2 and the 
best positions of ligands and receptors are shown in 
Figure 2. 
Docking Molecular and Interaction
 Prediction of antiangiogenic activity was 
done by docking heliannuol A-E compounds with 
Vascular Endothelial Growth Factor (VEGFR-2) 
(3WZE) receptors which were previously validated 
by receptors by redocking molecules to select the 
most ideal chain. The selection of this chain is seen 
from the results of the RMSD values obtained in the 
redocking process. The RMSD value less than 2Å 
is considered to have performed successfully and 
was found that poses reseptor with native ligand 
has valid (Pratama, 2015). Based on the validation 
results of the 3WZE receptors mentioned in Table 
2, an RMSD value of 0.285606 is accurate for 
docking simulations performed on BAX-1202 or 
N-methylpyridine-2-carboxamide native ligands. 
Whereas in cavity 1 the RMSD value is 11.5391 
(more than 2), so that is used for molecular docking 
at BAX-1202 cavity 2.
 The rerank score used in MVD is a 
weighted combination of the terms used by 
the MolDOck score mixed with a few addition 
terms which includes the steric term which are 
Lennard Jones approximations to the steric energy 
No  C ompound Formula Structure Toxicity 
LD50 
Lipinski 
rules of five 







860 mg/kg  MW 250.338 










482 mg/kg  MW 248.322 











500 mg/kg  MW 248.322 










2148 mg/kg  MW 250.338 










500 mg/kg  MW 248.332 




Table 1. Prediction of physical and chemical properties and toxicity.
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(Thomsen R, 2006). The reranking score function 
is computationally more expensive than scoring 
function used during the docking simulation, but 
it generally gives better result than docking score 
function. The reranking coefficients used the energy 
parameters such as E-Inter total, E-Inter (protein-
ligand), steric, VdW (Van de Waal’s), Hbond, 
E-Intra (tors, ligand atoms), E-Solvation, E-Total 
etc. In addition as shown in Figure 2, heliannuols 
B, heliannuol C and Sorafenib were found to be 
lying deep inside the binding pocket of Glu885 
and Asp1046which is an andication of a strong 
molecular interaction exhibiting both bonded and 
non bonded interaction.
 Comparison  of  the  amino  acid  residues 
of  the active  pocket  3WZE  using MVD and can 
be seen in Table 3. Table 3 showed the similarity of 
amino acid residues that were known by MVD. Its 
analysis was based on the principle of the interaction 
energy between macromolecules with a van der 
Waals loop to fi pockets that are considered the most 
favored binding by the ligand from the energy point 
of view (ie, pocket bonding interactions lowest 
energy).
DISSCUSSION
 This study aims to predict the physico-
chemical, toxicity, and antiangiogenesis properties 
of heliannuols. Several rules are developed in or-
der to guide the selection of compounds in the early 
phase of drug discovery or to prepare the chemical 
compounds. Among the first applications of physi-
cochemical properties in drug discovery, the rule of 
five (RO5) was formulated in 1997 by Lipinski and 
colleagues (Lipinski, et al., 2001). The RO5 states 
that a compound is more likely to be membrane per-
meable and easly absorbed via passive diffusion in 
human intestine if it matches the following criteria 
log-P≤5; MW≤500; HBA (O+N atom count)≤10 
and HBDs OH + NH count)≤5.
 Lipinski’s RO5 have been met by the five 
test compounds, heliannuol A-E, so that the test 
compounds can be expected to have strong ab-
sorption and permeability. As a consequence of the 
measurement of molecular weight, the compound 
heliannuol AE has been found to have a meaning in 
the recommended range with a molecular weight of 
less than 500 Da and a molecular weight of HB=H-








Cavity 1  Cavity 2 
RMSD Score 1 1.5391  0.285606 21.9229 
 
Table 2. VEGFR-2 (3WZE) receptor validation results.
Figure 2. A. The best positions of the five heliannuol compounds against the 3WZE receptor with amino 
acid residues are shown stick style with ligands indicated by thick lines with fixed color. B. The best 
positions of the five heliannuol compounds against the 3WZE receptor.
A. B.
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C=HE<HA=HD. Molecular weight determines the 
diffusion ability of a compound penetrate lipid bi-
layers in cell membranes (Cohen BE, et al., 1996).
 The partition coefficient (Log P) is the 
logarithmic value of the ratio of the solubility of 
compounds in organic solutions (octanol) to the 
solubility of compounds in water that determine the 
lipophilicity properties of a compound (Mannhold, 
et al., 2009). As a result of the prediction of the Log 
P, it is found that the compound heliannuol A-E 
meets Lipinski’s RO5, which is less than 5.
 The HBA and HBD are other important 
parameters related to compounds polarity and per-
meability. According to Lagorce, et al (2017), com-
pounds containing more HBA with less HBD have 
favorable profile for both these parameters. This is 
consistent with previously reported papers men-
tioned that HBD are often the “enemy of medical 
chemist” (i.e., large number of HBD could be the 
cause of poor permeability absorbtion and bioavail-
ability) (Baell, et al., 2013). As a result of permea-
bility prediction, the test compound has a value of 
less than 10 in the HBA and less than 5 in HBD, 
which means that the heliannuol A-E compound has 
a good permeability.
 As a result of the prediction of the polar sur-
face area (PSA) test in silico, it was found that each 
heliannuol had a high PSA value, making it possible 
to   penetrate the  blood  brain  barrier   moderately. 
The PSA is a parameter to describe the ability of a 
compound to penetrate the blood brain barrier, wa-
ter solubility and toxicity. The PSA is considered 
low if the PSA value<75Å2 and can cause an in-
crease in toxic risk, while PSA>80Å2 can penetrate 
the blood brain barrier (Hughes, 2008).
 Prediction of LD50 toxicity as a conse-
quence of, the compound heliannuol A-E is classi-
fied as class 4 and 5 with a range of LD50 566-1213 
which means it is less toxic. The higher the LD50 
value, the lower the toxicity. Class 4 means that 
the compounds show relatively low toxicity (Rao, 
2019). The highest toxicity levels of HD>HA>HC-
=HE>HB are as follows.
 The results of molecular docking in Table 3 
shows that the average score of heliannuol E com-
pounds are the smallest values compared to others, 
namely -75.5164. This indicates that the compound 
heliannuol E has a high affinity and approaches 
the rerank score of sorafenib as a reference com-
pound. The increasingly negative score indicates 
Figure 3. Two dimensions shape of the bond and the best way of the five heliannuol compounds to the 
3WZE receptor with amino acid residues that are indicated by the stick force with the ligands are 
shown with a thick line with a fixed color; blue lines as hydrogen bond and red lines as steric bond.
96
Muti’ah, et al., 2021
Indones. J. Cancer Chemoprevent., 12(2), 90-98
a more stable receptor drug binding and predicted 
better activity, but lower than Sorafenib. Increased 
activity in the Sorafenib analog compound could 
be the highest electronegativity value for F in the 
halogen community due to electronic effect. In the 
presence of 3 F, atoms optimize receptor interactions 
that have an effect on bond stability and behavior. 
In addition to the Sorafenib there is an urea group 
(-NHCONH-) which functions as a pharmacophore 
in the ligand-receptor interaction process, whereas 
in the heliannuols there are only OH groups and C 
at the aromatic chain (Dai, et al., 2008; Curtin, et 
al., 2012). The HE>HB>HC>HA>HD is the largest 
compound affinity sequence. 
 According to Temirak, et al. (2012), the key 
amino acids influence VEGFR-2 (3WZE) receptors, 
namely Glu885 and Asp1046. In addition to the 
amino acids Lys868 and Cys919, there is also a  typi-
cal hydrophobic association in the receptor tyrosine 
kinase between the aromatic rings of the ligand and 
the amino acid residues. Without these two main 
amino acids, the inhibitor effect on the VEGFR-2 
receptor will not occur. Sorafenib has 4 interactions 
at the VEGFR2 receptor. The  first  interaction is the 
phenyl urea chain from sorafenib, there is a hydro-
gen bridge between the glutamate chain and the N-H 
amide bond from aspartate which is the main key 
inhibitory activity. The second interaction is called 
the “selective area”, phenyl alanine is formed when 
it binds to a lipophilic pocket. Because  sorafenib 
has a meta-trifluoromethyl-para-chlorophenyl 
ring that binds to a hydrophobic pocket. The third 
interaction is called the “gatekeeper region”, the 
bonds are attractive to aromatic-aromatic interac-
tions involving triphosphate bonds. The fourth in-
teraction is the “hinge area”, there is a bond on the 
aromatic adenine ring and there is a hydrogen bond 
between the ATP region and the allosteric inhibition 
region. The N-methyl picolinamide from sorafenib 
contributes to this interaction.
 Based on the docking results of the five 
Heliannuol compounds, it was found that the he-
liannuol A, heliannuol D, and heliannuol E com-
pounds showed the desired results with the inter-
action of the amino acids Glu885 and Asp1046 
according to Table 3. The three heliannuol com-
pounds namely A, D, and E showed  interac-
tions  according to pharmacophore. Whereas the 
heliannuol B compounds only bind to the amino 
acid Cys 919, the heliannuol C compounds only 
bind to the amino acid Asp 1046 (Dai, et al., 2008; 









 [HA] -56.9496 Lys 868 ( 3.10);  Asp  1046 
(2.60); Cys 1045 ( 2.81); H is 
1026 (2.70) 
Asp 1046 (3.19); Glu 885 (3.15); Val 899 (2.61 
& 3 .17); Leu 1019 ( 2.82); I le 892 ( 3.07); H is 
1026 (3.09) 
 [HB] -70.83646 Cys 919 (3.24 & 2.60); Leu 840 
(2.63) 
Lys 920 (3.01); Cys 919 (2.92); Leu 840 (3.05 & 
3.16) 
 [HC] -61.3292 Asp 1046 ( 3.10);  Ile  1044 
(3.10) 
Asp 1046 (3.06); Ile 888 (3.06); Ile 892 (2.67); 
Leu 889 (2.72); Cys 1045 (3.12) 
 [HD] -49.61646 Glu 885 (2.90); Lys 868 (3.01)  Leu 1 019 (3.09); Ile 1044  (2.98); Cys 1045 
(3.06); Val 899 (3.12); Glu 885 (2.83); Asp 1046 
(3.16) 
 [HE] -75.5164 Asp 1046 ( 3.10); H is  1026 
(3.42) 
Asp 1046 (3.15); Glu 885 (3.13); Leu 889 (2.91) 
Sorafenib -128.0683 Glu 885 (2.70) Ile 1044 (2.96); Ala 866 (3.16); Val 848 (2.73) 
Table 3. Hydrogen bonding, steric bonding, and rerank score.
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 The molecular docking studies show that 
Heliannuol compounds have fulfilled the five 
Lipinski laws and possibly possessed low toxicity. 
Molecular docking simulation showed heliannuol 
A, heliannuol D, and heliannuol E compounds in-
teract with VEGFR-2 (PDB ID: 3WZE) as indicated 
by the interaction with the amino acids Glu885 
and Asp1046. However heliannuol and Sorafenib 
clearly showed different modes of binding and 
interaction of active site amino acid. Thus, based 
on previous report, our study  also shows   good 
binding capacity of heliannuol compared to the 
positive drug sorafenib. Therefore, further investi-
gations should be carried out and comfirmed by in 
silico studies on receptor targets or the observation 
of other identified therapeutic target and molecular 
mechanism for future clinical applications.
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